Glaukos Corporation
NYSE:GKOSMedical - Devices
-$0.18 today
- Market cap
- $13.80B
- Beta
- 0.81
- P/E (TTM)
- -39.0
- EPS (TTM)
- -$3.26
Volume 1.12M
Average 0.94M
GKOS Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Glaukos CorporationNYSE: GKOS
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin widens to 81.7%
Gross margin was 81.7% in Q2 FY2026, up 3.3 pp from a year earlier. On a trailing-twelve-month basis it was 79.1%, up 2.8 pp year over year. Over 3 fiscal years it widened by 1.9 pp.
Context
- Gross margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 77.5%
- Year-over-year change
- +2.0pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 77.5% | +2.0pp |
| FY2024 | 2024-12-31 | 75.5% | -0.5pp |
| FY2023 | 2023-12-31 | 76.0% | +0.4pp |
| FY2022 | 2022-12-31 | 75.6% | -1.7pp |
| FY2021 | 2021-12-31 | 77.3% | — |
Gross Margin vs competitors
How GKOS compares with its peers on the latest reported figures
- GKOS's LTM Jun 2026 gross margin of 79.1% is the 3rd highest of the 8 companies compared; the peer median is 76.5%.
- Its year-over-year change of +2.8 pp is the 2nd highest of 8, against a peer median of +0.5 pp.
- Over three fiscal years its change of +1.9 pp compares with a peer median of +0.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 87.2% | -3.4 pp | -3.9 pp | |
| LTM Mar 2026 | 86.2% | +0.5 pp | +3.5 pp | |
| LTM Jun 2026 | 79.1% | +2.8 pp | +1.9 pp | |
| LTM Mar 2026 | 77.0% | +9.7 pp | +33.1 pp | |
| LTM Mar 2026 | 76.5% | -16.8 pp | +13.5 pp | |
| LTM Apr 2026 | 76.4% | +2.4 pp | -2.4 pp | |
| LTM Sep 2026 | 57.3% | +2.2 pp | +0.8 pp | |
| LTM Jun 2026 | 57.2% | +0.3 pp | -4.9 pp | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding GKOS) | 76.5% | +0.5 pp | +0.8 pp | |
Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 294.01M | 282.86M | 314.71M | 383.48M | 507.44M |
| Cost of Revenue | 66.63M | 68.98M | 75.58M | 94.03M | 114.23M |
| Gross Profit | 227.38M | 213.88M | 239.14M | 289.45M | 393.22M |
| Gross Margin | 77.3% | 75.6% | 76.0% | 75.5% | 77.5% |
| Research & Development | 101M | 123.27M | 138.77M | 136.43M | 150.61M |
| Selling, General & Admin | 179.26M | 192.93M | 224.07M | 262.85M | 329.34M |
| Operating Expenses | 260.26M | 296.2M | 367.84M | 411.82M | 479.95M |
| Depreciation & Amortization | 34.42M | 35.95M | 37.98M | 39.92M | 42.35M |
| EBITDA | (1.47M) | (48.76M) | (82.12M) | (95.64M) | (146.06M) |
| EBITDA Margin | -0.5% | -17.2% | -26.1% | -24.9% | -28.8% |
| Operating Income | (32.87M) | (82.31M) | (128.7M) | (122.37M) | (86.73M) |
| Operating Margin | -11.2% | -29.1% | -40.9% | -31.9% | -17.1% |
| Interest Income | 1.29M | 2.38M | 9.16M | 11.11M | 10.71M |
| Interest Expense | 13.37M | 13.72M | 13.63M | 10.04M | 4.64M |
| Other Income / Expenses | (16.4M) | (16.12M) | (5.03M) | (23.24M) | (106.31M) |
| Income Before Tax | (49.27M) | (98.43M) | (133.73M) | (145.6M) | (193.04M) |
| Pre-Tax Margin | -16.8% | -34.8% | -42.5% | -38.0% | -38.0% |
| Income Tax Expense | 326K | 766K | 934K | 771K | (5.35M) |
| Net Income | (49.59M) | (99.2M) | (134.66M) | (146.37M) | (187.69M) |
| Net Margin | -16.9% | -35.1% | -42.8% | -38.2% | -37.0% |
| EPS (Basic) | (1.07) | (2.09) | (2.78) | (2.77) | (3.28) |
| EPS (Diluted) | (1.07) | (2.09) | (2.78) | (2.77) | (3.28) |
| Weighted Avg Shares | 46.42M | 47.44M | 48.43M | 52.76M | 57.19M |
| Weighted Avg Shares (Diluted) | 46.42M | 47.44M | 48.43M | 52.76M | 57.19M |
Glaukos Corporation
NYSE:GKOS
Intrinsic Alpha fair value
Locked
Current Price
$233.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.